Latest News, Articles, Research and Reports

sample of glaucoma mobile phone app screen

Article about a free mobile app that demystifies glaucoma – helping to explain symptoms, impact and treatment to patients and their families. You can read the full article here

Gus Gazzard lecture on SLT to over a thousand ophthamalogists in China on 21 February 23 China SLT Webinar 21 Feb 2023

eyetube logo

Sarwat Salim, MD, FACS, sits down with Gus Gazzard, MD, FRCOphth, to discuss the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. Dr. Gazzard details the study design, efficacy data, and cost effectiveness of selective laser trabeculoplasty versus medication. You can read more and see a preview video here

Ophthalmology Times logo

Professor Gazzard’s work is covered in this piece from November 2019 published in the  Ophthamalogy Times Europe magazine. You can read the full article here

NIHR logo

The National Institute for Health Research (NIHR) Dissemination Centre has published an NIHR Signal on Professor Gazzard’s research. You can read the Signal here: A laser eye procedure can be effective and safe if used early as a treatment for glaucoma

The Lancet Logo

The prestigious medical journal The Lancet published results from a pioneering research study, funded by the National Institute of Health Research (NIHR) and led by Professor Gus Gazzard. Read the article published in The Lancet here

The Daily Mail logo

An article from the Daily Mail about glaucoma surgery that quotes Professor Gazzard. You can  read the article here 

The Daily Mail logo

Guy Staniforth, 62, a project engineer from Greenwich in South-East London, describes having a glaucoma operation with Professor Gazzard. You can read the full article here

hydrus stent image

PARIS — The HORIZON trial at 3 years demonstrated that the Hydrus Schlemm’s canal stent added sustained IOP lowering to that achieved by cataract surgery alone, Gus Gazzard, MD, MBBChir, FRCOphth, said at the European Society of Cataract and Refractive Surgeons meeting. “That intraocular pressure was stable, significantly better than control after 3 years,” Gazzard said. Read the full article here

UCL logo

Speaking of his promotion and clinical trials, Gus said: “I am honoured to have been appointed to a UCL Professorship and I look forward to further developing the clinical trials and excellent postgraduate clinical education that we have established here at the UCL Institute of Ophthalmology. The clinical trials that I work on across the globe are a testament to the great team that I’ve been able to build at the Institute of Ophthalmology and Moorfields Eye Hospital, and a tribute to all of their hard work – the energy they bring to answer questions of real clinical importance to patients with blinding diseases.” You can read more here

the ophthalmologist logo

SLT is an effective intervention for newly-diagnosed patients – and now we can prove it. This is an article about the research conducted by Professor Gazzard. Read The Ophthalmologist article here

the guardian logo

Lasers should become the principal method in the UK for treating patients with the debilitating eye condition glaucoma. That is the stark conclusion of a three-year study published recently. Read the full article in The Guardian here

nhs logo

Gus has been awarded the prestigious, competitively awarded “NHS National Silver Merit Award”. These awards recognise NHS consultants who perform ‘over and above’ the standard expected of their role.

moorfields eye charity logo

The Moorfields Eye Charity Flipbook magazine has a feature articles on Professor Gazzard’s innovative research. You can read the Flipbook feature here

hydrus stent image

Professor Gazzard is now one of only three surgeons performing the innovative Hydrus stent procedure in the UK. Read more about the Hydrus procedure here or download a PDF about Hydrus here